Jump to content

Mafoprazine

From Wikipedia, the free encyclopedia
(Redirected from Draft:Mafoprazine)

Mafoprazine
Clinical data
Trade namesMafropan
AHFS/Drugs.comMonograph
Identifiers
  • N-[4-[3-[4-(2-fluorophenyl)piperazin-1-yl]propoxy]-3-methoxyphenyl]acetamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H28FN3O3
Molar mass401.482 g·mol−1
3D model (JSmol)
  • COC1=C(OCCCN2CCN(CC2)C3=C(F)C=CC=C3)C=CC(NC(C)=O)=C1
  • InChI=1S/C22H28FN3O3/c1-17(27)24-18-8-9-21(22(16-18)28-2)29-15-5-10-25-11-13-26(14-12-25)20-7-4-3-6-19(20)23/h3-4,6-9,16H,5,10-15H2,1-2H3,(H,24,27) checkY
  • Key:PHOCQBYGUQPMIB-UHFFFAOYSA-N checkY

Mafoprazine is an antipsychotic of the phenylpiperazine class which is used in veterinary medicine.[1] Intramuscular injections of mafoprazine mesylate are used for the sedation of pigs either on its own,[2] or in combination with sodium pentobarbital[3] or thiopental.[4]

Pharmacology

[edit]
Mafoprazine
Site Ki (nM) Species Ref
D2 10.7 Rat [5][6]
α1 12.7 Rat [5][6]
α2 101.0 Rat [5][6]

It demonstrates activity as a D2 dopamine receptor antagonist, an α1 adrenergic receptor antagonist, and an α2 adrenergic receptor agonist.[5]

The affinity of mafoprazine for D2 dopamine receptors is 6 and 16 times lower than that of chlorpromazine and haloperidol, respectively, but 2 times higher than that of azaperone.[5]

The Ki for various receptors was determined using rat neuronal receptor binding assays.[citation needed]

History

[edit]

Mafoprazine was first synthesized in 1988.[5] It is sold as Mafropan® by DS Pharma Animal Health Co. Ltd., Osaka, Japan.

References

[edit]
  1. ^ "Mafoprazine | Chemical Substance Information". J-GLOBAL. Japan Science and Technology Agency. J-GLOBAL ID: 200907023639364356.
  2. ^ Heishima K, Kuo K, Kimura M, Mori T (2019). "Animal Lymphocyte Metaphase Chromosome Preparation". Radiation Cytogenetics. Methods in Molecular Biology. Vol. 1984. pp. 7–22. doi:10.1007/978-1-4939-9432-8_2. ISBN 978-1-4939-9430-4. PMID 31267415. S2CID 195787061.
  3. ^ Azizi AF, Miyazaki R, Yumito T, Ohashi Y, Uno S, Miyajima U, et al. (January 2018). "Effect of maternal supplementation with seaweed powder on immune status of liver and lymphoid organs of piglets". The Journal of Veterinary Medical Science. 80 (1): 8–12. doi:10.1292/jvms.17-0537. PMC 5797852. PMID 29142150.
  4. ^ Umeyama K, Watanabe K, Watanabe M, Horiuchi K, Nakano K, Kitashiro M, et al. (April 2016). "Generation of heterozygous fibrillin-1 mutant cloned pigs from genome-edited foetal fibroblasts". Scientific Reports. 6 (1): 24413. Bibcode:2016NatSR...624413U. doi:10.1038/srep24413. PMC 4830947. PMID 27074716. S2CID 22352477.
  5. ^ a b c d e f Fukuchi I, Kawashima K, Matsuoka Y, Ishida R (May 1988). "Neurochemical study of mafoprazine, a new phenylpiperazine derivative". Japanese Journal of Pharmacology. 47 (1): 51–61. doi:10.1254/jjp.47.51. PMID 3411821. S2CID 13158367.
  6. ^ a b c "MAFOPRAZINE". NCATS Inxight Drugs. U.S. National Center for Advancing Translational Sciences (NCATS).